BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song C, Qian X, Zhu Y, Shu X, Song Y, Xiong Z, Ye J, Yu T, Ding L, Wang H, Lu N, Xie Y. Effectiveness and safety of furazolidone‐containing quadruple regimens in patients with Helicobacter pylori infection in real‐world practice. Helicobacter 2019. [DOI: 10.1111/hel.12591] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Hu Y, Zhu Y, Lu NH. Recent progress in Helicobacter pylori treatment. Chin Med J (Engl). 2020;133:335-343. [PMID: 31929363 DOI: 10.1097/cm9.0000000000000618] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
2 O'connor A, Furuta T, Gisbert JP, O'morain C. Review – Treatment of Helicobacter pylori infection 2020. Helicobacter 2020;25. [DOI: 10.1111/hel.12743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Resina E, Gisbert JP. Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection. Antibiotics (Basel) 2021;10:1028. [PMID: 34572610 DOI: 10.3390/antibiotics10091028] [Reference Citation Analysis]
4 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
5 Wang J, Cao Y, He W, Li X. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine (Baltimore) 2021;100:e28323. [PMID: 34941132 DOI: 10.1097/MD.0000000000028323] [Reference Citation Analysis]
6 Qiao C, Li Y, Liu J, Ji C, Qu J, Hu J, Ji R, Wan M, Lin B, Lin M, Qi Q, Zuo X, Li Y. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area. J Gastroenterol Hepatol 2021. [PMID: 33691344 DOI: 10.1111/jgh.15468] [Reference Citation Analysis]
7 Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother 2021;22:729-41. [PMID: 33131337 DOI: 10.1080/14656566.2020.1845649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Shiotani A, Roy P, Lu H, Graham DY. Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Therap Adv Gastroenterol 2021;14:17562848211064080. [PMID: 34987609 DOI: 10.1177/17562848211064080] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Liu A, Wang Y, Song Y, Du Y. Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection. Saudi J Gastroenterol 2020;26:78-83. [PMID: 32295932 DOI: 10.4103/sjg.SJG_589_19] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Liu B, Xu X, Tong H, Zhu Z, Tang W, Zhang Y, Tang C. Synthesis and Antiproliferative Evaluation of Novel 5-Aryl Substituted Oxazolo[4,5- b ]pyridin-2-amine Derivatives. Organic Preparations and Procedures International 2021;53:528-36. [DOI: 10.1080/00304948.2021.1968756] [Reference Citation Analysis]
11 Liu J, Ji CR, Li YY, Qiao C, Hu JN, Wan M, Lin MJ, Lin BS, Wang J, Zha J, Li LX, Zuo XL. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study. Clin Transl Gastroenterol 2021;12:e00391. [PMID: 34397042 DOI: 10.14309/ctg.0000000000000391] [Reference Citation Analysis]
12 Feitosa IB, Mori B, Santos APAD, Villanova JCO, Teles CBG, Costa AG. What are the immunopharmacological effects of furazolidone? A systematic review. Immunopharmacol Immunotoxicol 2021;43:674-9. [PMID: 34570666 DOI: 10.1080/08923973.2021.1979034] [Reference Citation Analysis]